Adma Biologics (ADMA) Misses Q2 EPS by 8c

Adma Biologics (NASDAQ: ADMA) reported Q2 EPS of ($0.44), $0.08 worse than the analyst estimate of ($0.36). Revenue for the quarter came in at $1.3 million, versus $1.5 million reported last year.

For earnings history and earnings-related data on Adma Biologics (ADMA) click here.

You May Also Be Interested In

• Important Notice to Long-Term Shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA); GeneDx Holdings Corp. (NASDAQ: WGS); Navan, Inc. (NASDAQ: NAVN); and New Era Energy & Digital, Inc. (NASDAQ: NUAI) (F
• Occidental Petroleum releases Q2 2026 earnings considerations
• Financial Select Sector SPDR ETF (XLF) spreader of 20K contracts of July 31 weekly 57 and 59 calls into bank earnings season